Bridging tumor moats with potent drug delivery particles

January 10, 2018, American Chemical Society
Credit: American Chemical Society

Despite herculean efforts, cancer remains a formidable disease, with each malignant subtype responding differently to therapeutics. One hurdle specific to treating solid tumors is a protective layer called an extracellular matrix that can prevent chemotherapeutic agents from penetrating the tumor's core. Scientists now report results in ACS' Chemistry of Materials showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.

For tumors that can't be extracted with surgery, radiation and chemotherapy are the treatments of choice, but both can involve serious side effects due to a lack of specificity: They'll kill healthy cells along with malignant ones. Researchers have long known that, thanks to the unique blood vessel architecture surrounding tumors, nanoparticles can easily pass into the cancer zone, offering a potential route for the specific delivery of chemotherapies to cancer cells. However, efforts to exploit this phenomenon have fallen short, with experimental -loaded particles failing because they can't get through the dense extracellular matrix or they lose the therapeutic payload en route to the 's interior. Alejandro Baeza, C. Jeffrey Brinker, Maria Vallet-Regi and colleagues addressed this shortcoming by developing a brand-new type of particle.

The researchers created a "protocell," a nanoparticle that can carve through the extracellular matrix, delivering cell-killing doses of drug to the deepest tumor regions. To develop the protocell, the team started with a mesoporous silica skeleton with a high internal surface area that can contain a large amount of drug. They surrounded this skeleton with a lipid bilayer outfitted with an array of tools to help the protocell deliver its drug arsenal to the desired locale, including enzymes that cleave collagen, a major component of the tumor's . The protocell also features pH-sensitive ligands that trigger the release of the drug upon entry into the relatively acidic interior of a cell, ensuring the medication is only delivered where needed. The researchers tested the protocells in a 3-D cell culture model of a solid tumor, showing that the protocell penetrates and destroys malignant cells better than drug-loaded protocells without the enhanced toolkit.e potential to one day treat cancer and other diseases in the .

Explore further: Researchers create unique bioengineered organoids for modeling colorectal cancer

More information: María Rocío Villegas et al. Multifunctional Protocells for Enhanced Penetration in 3D Extracellular Tumoral Matrices, Chemistry of Materials (2017). DOI: 10.1021/acs.chemmater.7b03128

Abstract
The high density of the extracellular matrix in solid tumors is an important obstacle to nanocarriers for reaching deep tumor regions and has severely limited the efficacy of administrated nanotherapeutics. The use of proteolytic enzymes prior to nanoparticle administration or directly attached to the nanocarrier surface has been proposed to enhance their penetration, but the low in vivo stability of these macromolecules compromises their efficacy and strongly limits their application. Herein, we have designed a multifunctional nanocarrier able to transport cytotoxic drugs to deep areas of solid tumors and once there, to be engulfed by tumoral cells causing their destruction. This system is based on mesoporous silica nanocarriers encapsulated within supported lipid bilayers (SLBs). The SLB avoids premature release of the housed drug while providing high colloidal stability and an easy to functionalize surface. The tumor penetration property is provided by attachment of engineered polymeric nanocapsules that transport and controllably unveil and release the proteolytic enzymes that in turn digest the extracellular matrix, facilitating the nanocarrier diffusion through the matrix. Additionally, targeting properties were endowed by conjugating an antibody specific to the investigated tumoral cells to enhance binding, internalization, and drug delivery. This multifunctional design improves the therapeutic efficacy of the transported drug as a consequence of its more homogeneous distribution throughout the tumoral tissue.

Related Stories

Promising target for treating brain tumors in children

November 28, 2017

Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental ...

Researchers deliver first 'nanotherapeutics' to tumor

May 15, 2017

For the first time, WSU researchers have demonstrated a way to deliver a drug to a tumor by attaching it to a blood cell. The innovation could let doctors target tumors with anticancer drugs that might otherwise damage healthy ...

Recommended for you

Producing defectless metal crystals of unprecedented size

October 19, 2018

A research group at the Center for Multidimensional Carbon Materials, within the Institute for Basic Science (IBS), has published an article in Science describing a new method to convert inexpensive polycrystalline metal ...

Nanodiamonds as photocatalysts

October 19, 2018

Climate change is in full swing and will continue unabated as long as CO2 emissions continue. One possible solution is to return CO2 to the energy cycle: CO2 could be processed with water into methanol, a fuel that can be ...

Shining light on the separation of rare earth metals

October 18, 2018

Inside smartphones and computer displays are metals known as the rare earths. Mining and purifying these metals involves waste- and energy-intense processes. Better processes are needed. Previous work has shown that specific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.